CMV infection · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to lower CMV infection compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Wound complications · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
All malignancies · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in all malignancies compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher number needing to change treatment compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New onset of diabetes · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher new‐onset diabetes mellitus compared with antimetabolites: secondary outcomes (moderate certainty).
1 finding from 1 review
BK virus infection · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) leads to lower BK virus infection compared with antimetabolites: secondary outcomes (high certainty).
1 finding from 1 review
GFR · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher hypercholesterolaemia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Hypertriglyceridaemia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher hypertriglyceridaemia compared with antimetabolites: secondary outcomes (moderate certainty).
1 finding from 1 review
Leucopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to lower leucopenia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Death (all causes) · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in death (all causes) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Graft loss including death · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients
Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
CMV infection · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Malignancy · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).
1 finding from 1 review
Diabetes · primary immunosuppression in kidney transplant recipients
Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review